Introduction {#Sec1}
============

Osteoporosis is a major public health concern that results in considerable fracture-related morbidity and mortality \[[@CR1]--[@CR3]\]. In Canada, oral bisphosphonates (alendronate, etidronate, and risedronate) are the most commonly prescribed agents for treating osteoporosis and preventing fractures \[[@CR3], [@CR4]\]. However, persistence with therapy is suboptimal and linked to reduced drug effectiveness \[[@CR5]--[@CR8]\]. Prior systematic reviews document that fewer than half of patients persist with osteoporosis treatment for a full year \[[@CR5], [@CR9], [@CR10]\], with estimates ranging between 18% and 78% for bisphosphonates \[[@CR11], [@CR12]\]. An underreported finding is that many patients who discontinue bisphosphonate therapy reinitiate treatment after an extended gap \[[@CR13]\]. To further explore this issue, we studied all new users of oral bisphosphonates among older adults in Ontario from April 1996 to March 2009. We hypothesized that the majority of patients would discontinue treatment, yet a significant proportion would return to therapy after an extended gap in therapy. We also hypothesized that many patients would experience more than one extended gap in therapy, yet cumulative exposure to oral bisphosphonates would exceed 1 full year of therapy in most patients.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

We used Ontario healthcare utilization (medical and pharmacy) databases to identify, characterize and follow all new users of oral bisphosphonates aged 66 or more years in Ontario since 1996. Ontario medical and pharmacy claims databases are widely used for research purposes, and several studies demonstrate data quality \[[@CR14]--[@CR18]\]. Medicare services are funded through comprehensive universal health insurance for all Canadian residents, and residents of Ontario aged 65 or more years qualify for pharmacy coverage through the Ontario Drug Benefit (ODB) program \[[@CR19]\]. The ODB Formulary has included unrestricted access to cyclical etidronate since 1996 and alendronate and risedronate since 2007.

Study cohort {#Sec4}
------------

We identified new users of alendronate (5, 10, and 70 mg), cyclical etidronate and risedronate (5 and 35 mg) using ODB program data from April 1, 1996 to March 31, 2009. The first date of bisphosphonate dispensing over the entire study period was considered the index date. To ensure a minimum 1 full year of pharmacy claims history, we restricted inclusion to those aged 66 years or older at index date. We also excluded patients with Paget's disease diagnosis and patients with any prescription related to osteoporosis (bisphosphonate, calcitonin, raloxifene, or teriparatide) in the year prior to the index date. For descriptive purposes, we defined age at index, and identified bone mineral density (BMD) testing, and fracture history within 1 year prior to the index date (Appendix [1](#Sec12){ref-type="sec"}). BMD testing was identified using billing codes for Dual-Photon Absorptiometry (DPA) prior to 1998 and Dual-energy X-ray Absorptiometry (DXA) from 1998 to 2009. These codes have an estimated sensitivity of 98% and specificity of 93% for identifying BMD testing in Ontario \[[@CR18]\]. Fractures were identified using outpatient and inpatient billing claims. Prior to April 2002, inpatient diagnoses were coded using ICD ninth revision, clinical modification (ICD-9-CM). Since then, the Canadian tenth revision (ICD-10-CA) codes have been used.

Measuring persistence with therapy {#Sec5}
----------------------------------

We determined persistence with therapy using ODB (pharmacy claims) data. ODB data include the days supplied and thus we can calculate when a patient is expected to refill their prescription. We defined persistence as continuous treatment without an interruption (gap) exceeding 60 days (Fig. [1](#Fig1){ref-type="fig"}). In a secondary analysis, we extended the permissible gap length to 120 days. These gap lengths are consistent and comparable with prior research on persistence with osteoporosis pharmacotherapy \[[@CR20]--[@CR23]\]. When calculating persistence, overlap of the same drug and regimen was additive; however, a switch between agents or from daily to weekly dosing of the same drug was considered continuous use with no overlap granted. Values for missing days supplied were imputed prior to 1997 when this field was not reported in the ODB database; this included 13 patients dispensed alendronate (24 dispensing records), and all patients dispensed cyclical etidronate prior to 1997. We imputed a 60-day supply for alendronate---the median number of days supply for alendronate from 1997 to 1999. A 90-day supply was imputed for cyclical etidronate since it is dispensed as 14 days of active drug plus 76 days of calcium supplements. Fig. 1Defining persistence with therapy (adapted from Cadarette et al. \[[@CR33]\]). Persistence with therapy after index was defined as continuous treatment without a gap \>60 days (primary analysis) and \>120 days (secondary analysis). Theoretical end of treatment must have occurred within the follow-up interval under investigation; however, pharmacy data after the theoretical treatment end date were used to identify whether or not an extended gap was relevant to define non-persistence. \*If the gap length between prescriptions was ≤60 days, then the patient was assumed to have persisted with therapy. \*\*Example when a patient reinitiates therapy after an extended gap. Some patients never reinitiate treatment and are defined in Table [2](#Tab2){ref-type="table"} as having discontinued therapy. Rx = Prescription

Statistical analysis {#Sec6}
--------------------

We compared the characteristics (age, sex, bisphosphonate at index, prior BMD testing, and fracture history) of new users across four time periods: April 1996--March 2000, April 2000--March 2003, April 2003--March 2006, and April 2006--March 2008. We then examined persistence with therapy and number of extended gaps (primary analysis gap length \>60 days and secondary analysis gap length \>120 days) between prescriptions according to follow-up periods ranging from 1 to 9 years after treatment initiation. Only those persons with complete follow-up information were included in each respective follow-up period, and therefore patients who died within the observation period were excluded from respective analyses. In a secondary analysis, we examine the length of time until return to therapy following a 120-day gap or longer by plotting a Kaplan--Meier curve that censored patients at time of death, emigration from the province or March 31, 2009---the last date of available data. Finally, we calculated the proportion of patients that filled only a single prescription, the proportion that switched to a different bisphosphonate, and the median days of exposure within 1 year after index, and over the entire follow-up period.

Results {#Sec7}
=======

Descriptive characteristics {#Sec8}
---------------------------

We identified 451,113 new bisphosphonate users meeting our inclusion criteria. Of these, 84% were female and the mean age was 75.6 years (SD = 6.9). From April 2000 to March 2009 fiscal year groups, we found that the proportion of male users increased over time (from 8.9% to 23.6%), etidronate use at index declined over time (from 91.0% to 22.5%), and BMD testing prior to treatment initiation has been stable at 63% since 2000 (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of new users of oral bisphosphonates^a^: Ontario residents aged 66 or more years, April 1996--March 2009April 1996--March 2000April 2000--March 2003April 2003--March 2006April 2006--March 2009Overall*N* = 106,456*N* = 119,468*N* = 119,326*N* = 105,863*N* = 451,113Age, mean (SD)75.1 (6.4)75.4 (6.7)76.0 (7.1)75.6 (7.2)75.6 (6.9)Males,%8.913.319.823.616.4Etidronate,%91.089.555.322.565.1BMD test,%^b^58.163.663.363.262.1Fracture history,%^c^ Thoracic vertebral0.10.20.20.20.2 Hip, humerus, radius/ulna5.45.56.26.55.9^a^Alendronate (5, 10, and 70 mg), cyclical etidronate and risedronate (5 and 35 mg).^b^BMD testing identified within 1 year prior to index date using Ontario Health Insurance Plan (OHIP) billing codes for dual photon absorptiometry (DPA) prior to 1998, and dual-energy X-ray absorptometry (DXA) from 1998 to 2009 (see Appendix [1](#Sec12){ref-type="sec"}).^c^Fractures were identified using ICD-9-CM codes before April 2002, and ICD-10-CA codes since April 2002 (see Appendix [1](#Sec12){ref-type="sec"}).

Persistence with bisphosphonate therapy {#Sec9}
---------------------------------------

A summary of persistence with bisphosphonate therapy over time is provided in Table [2](#Tab2){ref-type="table"}. In our primary analysis that used a 60-day permissible gap, we identified that the proportion of patients that persisted with therapy declined from 63% at 1 year to 12% after 9 years. We also identified that most patients experienced one or more extended gaps in bisphosphonate therapy. For example, among the 213,029 new users with at least 5 years of follow-up, 25% persisted with therapy for the full 5 years, 61% experienced one (24%) or more (37%) extended gaps in therapy, and 14% discontinued treatment without returning to bisphosphonate therapy. Using a more lenient 120-day permissible gap to define non-persistence, we note that persistence rates increased and fewer users were identified to have experienced extended gaps in drug therapy. For example, persistence at 1 year increased from 63% using a 60-day permissible gap to 77% when using a 120-day permissible gap (Table [2](#Tab2){ref-type="table"}). Figure [2](#Fig2){ref-type="fig"} represents the Kaplan--Meier curve for time until treatment reinitiation after at least 120 days without drug, that censors on date of death, and loss to follow-up. Here we note that 38% of patients returned to therapy within 1 year, 51% returned within 2 years, and 67% returned to therapy within 5 years. Table 2Proportion of new oral bisphosphonate^a^ users who persisted^b^ with therapy, discontinued therapy^c^ and experience one or more extended gaps in treatmentFollow-up years123456789*N*^d^402,791350,983302,444257,029213,029171,515134,09899,11868,45360-day permissible gap  Persisted with therapy^b^63.146.436.830.125.020.917.614.812.2  Discontinued therapy^c^15.215.815.314.614.013.412.712.011.4  Reinitiated therapy21.737.847.955.361.065.769.773.276.4    One extended gap16.723.224.524.724.323.622.921.920.7     ≥ 2 extended gaps5.014.623.430.636.742.146.851.355.7120-day permissible gap  Persisted with therapy^b^76.763.554.848.142.738.034.430.827.4  Discontinued therapy^c^16.818.618.718.618.318.017.517.416.9  Reinitiated therapy6.517.926.533.339.044.048.151.855.7    One extended gap6.415.920.623.325.026.227.027.427.9     ≥ 2 extended gaps0.12.05.910.014.017.821.124.427.8^a^Alendronate (5, 10, and 70 mg), cyclical etidronate, risedronate (5 and 35 mg) identified from the Ontario Drug Benefit (ODB) program data, residents aged 66 or more years. First dispensing over entire period from April 1996 to March 2009 was considered the index date.^b^Persistence with therapy after index was defined as continuous treatment without a permissible gap.^c^Identified as the proportion of patients who did not persist with therapy, and did not reinitiate treatment in the respective follow-up period.^d^Number of patients with complete follow-up data included and thus excludes those who died, moved out of the province, and if March 31, 2009 occurred within the follow-up period. Proportions therefore cannot be compared directly over time.Fig. 2Time until return to oral bisphosphonate therapy following a period of 120 days or longer without treatment among new users in Ontario aged 66 or more years, April 1996--March 2009

Number of prescriptions, total drug exposure and drug switching {#Sec10}
---------------------------------------------------------------

Patients were followed for a median length of 4.7 years (min = 0.5 years, max = 12.8 years). During the first year of therapy, 16% of users received only a single prescription of an oral bisphosphonate; however, this decreased to 10% when considering the entire follow-up period of up to 12.8 years. The median length of time covered by bisphosphonates before a period greater than 60 days without treatment was 0.9 years (SD = 2.5 years), and this increased to 2.2 years (SD = 2.8 years) when considering all episodes of use.

We found that 7% of new bisphosphonate users switched to a different bisphosphonate within 1 year of treatment initiation, and this increased to more than a third of patients (37%) over the entire duration of follow-up. Although fewer than 8% of etidronate users who initiated therapy between 1996 and 2003 switched to a different bisphosphonate within the first year of therapy, this increased to 51% over the entire follow-up period of up to 12.8 years. Among new users treated with alendronate or risedronate at the index date, only 5% switched therapy within one year and less than 10% switched over the length of follow-up.

Discussion {#Sec11}
==========

Our results are consistent with prior reports that indicate that persistence with bisphosphonate therapy is suboptimal \[[@CR10]--[@CR12]\]. Recent evidence suggests that uninterrupted bisphosphonate therapy for a minimum of 3--5 years is important to reduce fracture risk \[[@CR24]--[@CR27]\]. However, our results show that fewer than half of patients persist with therapy for 2 years, and only 25% persist with therapy for 5 years. Even when a more lenient permissible gap of 120 days was used to identify non-persistence, our findings identify that only 40% of patients persisted with therapy for 5 years. We also note that extending the permissible gap length from 60 to 120 days changed our estimates of persistence from 63% to 77% at 1 year, and from 25% to 43% at 5 years. These findings highlight the impact of length of follow-up and permissible gap on persistence measurement. Given the observed variation in persistence rates with different permissible gap lengths, we recommend that methodology be explicitly reported to facilitate study comparisons \[[@CR13]\].

Regardless of the permissible gap length used to determine length of treatment persistence, our findings identify that extended gaps in oral bisphosphonate therapy are common, and the majority of patients experience more than one extended gap between bisphosphonate prescriptions. Although it is encouraging that many patients are returning to therapy, the clinical impact of the time off drug remains unknown, and requires further investigation. In fact, experiencing a fracture after stopping osteoporosis treatment has been found to be a significant predictor of reinitiating osteoporosis medication \[[@CR20]\].

Our results also indicate that the longer the length of follow-up, the more likely it is that a patient will switch treatments. Over the entire study period of up to 12.8 years, 37% of all users (51% of etidronate users) switched to a different oral bisphosphonate. In Ontario, etidronate has been available without restriction through the ODB program since 1996, thus permitting greater opportunity for patients to initiate etidronate and switch to another bisphosphonate over time. Although second generation bisphosphonates have been available since 1996 (daily alendronate), the initial listing status for both alendronate and risedronate required a trial of, or documented allergy to etidronate (2000--2003), or two of the following: (i) BMD T-score ≤3.0 SD, (ii) aged 75 or more years, (iii) prior osteoporosis-related fracture (2003--2007). Since 2007, all three agents have been covered without restrictions. Given that clinical trial data demonstrate reductions in non-vertebral fracture risk compared to placebo with use of alendronate and risedronate, but not etidronate \[[@CR2], [@CR28]\], it is not surprising that patients were observed to have switched from etidronate to alendronate or risedronate after treatment failure, or once access to these drugs through the ODB program became less restrictive. We identified that less than 10% of alendronate/risedronate users switched to a different bisphosphonate over follow-up, compared to 51% of etidronate users. Switching rates between bisphosphonates may be lower in regions such as the United States, where etidronate is not available.

Despite the decline in etidronate prescribing over time and the noted increase in the number of males being treated, we found little change over time in the percent of new users having had a BMD test or fracture. The slight increase in BMD testing seen between April 1996--March 2000 and April 2000--March 2003 is likely attributable to the switch from DPA to DXA technology in 1998 and the increased number of DXA machines, from 95 in 1997 to 213 in 1998 \[[@CR29]\]. Similarly, the slight increase in the proportion with hip, humerus or radius/ulna fracture within the year prior to index is likely related to the change in coding from ICD-9-CM to ICD-10-CA that occurred in 2002. While ICD-10-CA includes greater specification, previous studies have found sensitivity of 95% or higher for the identification of fractures using ICD-9-CM \[[@CR30]\], and ICD-10-CA coding \[[@CR17]\]. Our results therefore suggest little change in the importance of BMD testing or fracture history in guiding bisphosphonate therapy over our study period.

Three important study limitations are worth noting. First, we were unable to study patterns of bisphosphonate therapy among persons younger than 66 years. It is possible that prescribing patterns have changed over time in ways that we were unable to observed, such as prescribing pharmacotherapy at younger ages and prior to 66 years. It is also possible that some of the identified "new users" were prevalent users with private drug coverage that switched to coverage under the ODB program once these agents were covered by the public plan. However, recent data suggest good agreement between self-report and ODB pharmacy data for bisphosphonate use among older women (kappa statistic = 0.81, 95% CI = 0.77--0.85 \[[@CR18]\]), and few seniors in Ontario do not access medications through the ODB program \[[@CR14]\].

Second, we restricted our study to oral bisphosphonates, and thus it is possible that some users classified as non-persistent with therapy may have switched to non-oral bisphosphonate therapy, such as calcitonin, raloxifene, teriparatide, or zoledronic acid. However, we expect this to have occurred in only a few patients, as calcitonin and teriparatide are not listed on the ODB formulary, and raloxifene and zoledronic acid are only available under restricted conditions. For example, zoledronic acid is only available among men and women unable to take oral medications. In addition, prior research has identified that those who return to osteoporosis therapy after an extended gap tend to return to the same drug class \[[@CR20]\]. Thus, while we recognize that switching between osteoporosis therapies may be more common in regions with better access to non-bisphosphonate therapy, we expect this to be minimal in our sample. Further research using large claims databases in other regions will help clarify switching patterns.

Third, we recognize that some of our observed non-persistence may have been physician directed due to the experience of, or concern for adverse drug events. Although oral bisphosphonates are generally well tolerated, upper gastrointestinal complaints are commonly reported in new users \[[@CR31]\]. In addition, with recent concerns for possible increased risk for femoral shaft fractures after long-term bisphosphonate use \[[@CR32]\], a physician directed drug holiday may be reasonable for those patients with more than 5 years of bisphosphonate use, and could account for some of the non-persistence seen beyond 5 years. While the median exposure was only 2.2 years, 25% of patients had 5 years of uninterrupted therapy, and 12% had 9 years of uninterrupted therapy.

Despite these limitations, our study has several strengths. We followed more than 450,000 new users of oral bisphosphonates for up to 12.8 years. This provided ample follow-up to characterize both drug switching and treatment reinitiation patterns. Our results indicate that most patients discontinue bisphosphonate therapy within 2 years and many experience more than one extended gap in bisphosphonate use. Although emerging evidence suggests that after 3--5 years of uninterrupted therapy a physician-directed drug holiday may be appropriate for many patients \[[@CR24]--[@CR26]\], further research is needed to clarify for which patients this may be suitable. In addition, we document that the majority of patients are not exposed to bisphosphonate therapy long enough to be considered for a physician-directed drug holiday, with a median length of exposure of only 2 years, and the majority experiencing one or more extended gaps in therapy.

Osteoporosis is a major public health concern that results in debilitating fractures. Oral bisphosphonates are first-line therapy for osteoporosis, and are effective in reducing fracture risk. Although other therapies are available, including nasal calcitonin, raloxifene, teriparatide, zoledronic acid, and most recently, denosumab; these agents are reserved as second or third line treatment options. Our results not only confirm findings from other countries by identifying sub-optimal rates of persistence with oral bisphosphonate, but our findings add to the literature by identifying the frequency of extended gaps and rate of return to therapy. We identify that many patients return to therapy following an extended gap; however, the clinical impact of this time away from therapy remains unknown. Further research is needed to identify predictors of non-persistence and to clarify when and among which patients a physician-directed drug holiday may be appropriate. Results may then be used to develop effective interventions that aim to improve the length of persistence and reduce the frequency of gaps in bisphosphonate therapy. It is through improved treatment rates among patients at high risk for fracture that we will we reduce the public impact of osteoporotic fractures.
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Appendix {#Sec12}
========

Table 3Medical claims used to identify covariates and exclusion criteriaVariableCoding definitionBMD testing^a^[Any OHIP claim of]{.ul}: J654, J655, J656, J688, J854, J855, J856, J888, X145, X146, X149, X152, X153, X155 and X157Paget's disease diagnosis[Any of ICD-9-CM]{.ul} = 731.0, 731.1; or [ICD-10-CA]{.ul} = M88.x; or [OHIP]{.ul} = 731Fracture historyThoracic vertebral fracture:[Any of ICD-9-CM]{.ul} = 805.2, 805.3 or [ICD-10-CA]{.ul} = S22.0x, S22.1xHip, humerus, radius or ulna:[Any of ICD-9-CM]{.ul} = 733.11, 733.12, 733.14, 812.x, 813.x, 820.x; or [ICD-10-CA]{.ul} = S42.2x, S42.3x, S42.4x, S52.x, S72.0x, S72.1x, S72.2x; or [OHIP]{.ul} = 812, 813, F027, F028, F030*ICD-9-CM* International Classification of Diseases, Ninth Revision, Clinical Modification; used prior to April 1, 2002; *ICD-10-CA* International Classification of Diseases, Tenth Revision, Canada; used since April 1, 2002; *OHIP* Ontario Health Insurance Plan claims database^a^Sensitivity = 98%, specificity = 93% \[[@CR18]\]
